IL173850A0 - Method for the in vitro titration of an ncta and application thereof in a method for the evaluation and/or monitoring of a biological product production method - Google Patents

Method for the in vitro titration of an ncta and application thereof in a method for the evaluation and/or monitoring of a biological product production method

Info

Publication number
IL173850A0
IL173850A0 IL173850A IL17385006A IL173850A0 IL 173850 A0 IL173850 A0 IL 173850A0 IL 173850 A IL173850 A IL 173850A IL 17385006 A IL17385006 A IL 17385006A IL 173850 A0 IL173850 A0 IL 173850A0
Authority
IL
Israel
Prior art keywords
ncta
monitoring
application
evaluation
vitro
Prior art date
Application number
IL173850A
Other versions
IL173850A (en
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of IL173850A0 publication Critical patent/IL173850A0/en
Publication of IL173850A publication Critical patent/IL173850A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)

Abstract

The invention relates to a method for the in vitro titration of a non-conventional transmissible agent (NCTA), using transgenic cell lines. The invention also relates to: the application of the aforementioned in vitro titration method in a method for the in vitro evaluation and/or monitoring of the effectiveness of a biological production or treatment method or of one or more steps in such a method for the elimination of an NCTA, and to the application thereof in a method for the in vitro evaluation and/or monitoring of a decontamination procedure.
IL173850A 2003-08-25 2006-02-21 Method for the in vitro titration of an ncta and application thereof in a method for the evaluation and/or monitoring of a biological product production method IL173850A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0310126A FR2859222B1 (en) 2003-08-25 2003-08-25 METHOD OF EVALUATING AND / OR CONTROLLING A PROCESS FOR OBTAINING A BIOLOGICAL PRODUCT LIKELY TO BE CONTAMINATED BY NON-CONVENTIONAL TRANSMISSIBLE AGENT (NCTA)
PCT/FR2004/002179 WO2005022148A1 (en) 2003-08-25 2004-08-23 Method for the in vitro titration of an ncta and application thereof in a method for the evaluation and/or monitoring of a biological product production method

Publications (2)

Publication Number Publication Date
IL173850A0 true IL173850A0 (en) 2006-07-05
IL173850A IL173850A (en) 2012-02-29

Family

ID=34130588

Family Applications (1)

Application Number Title Priority Date Filing Date
IL173850A IL173850A (en) 2003-08-25 2006-02-21 Method for the in vitro titration of an ncta and application thereof in a method for the evaluation and/or monitoring of a biological product production method

Country Status (12)

Country Link
EP (1) EP1658494B1 (en)
JP (1) JP2007503209A (en)
AT (1) ATE528646T1 (en)
AU (1) AU2004269188B2 (en)
BR (1) BRPI0413897A (en)
CA (1) CA2536688C (en)
DK (1) DK1658494T3 (en)
ES (1) ES2374816T3 (en)
FR (1) FR2859222B1 (en)
IL (1) IL173850A (en)
PL (1) PL1658494T3 (en)
WO (1) WO2005022148A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2885369B1 (en) * 2005-05-04 2010-11-12 Lab Francais Du Fractionnement PRION TYPE SYNTHETIC AND STANDARDIZED INFECTIOUS MATERIAL AND USES THEREOF AS INFECTING INOCULUM.
FR2929290B1 (en) * 2008-03-27 2010-05-07 Lfb Biotechnologies METHOD FOR IN VITRO DETECTION AND / OR TITRATION OF NON-CONVENTIONAL TRANSMISSIBLE AGENT
FR2935711A1 (en) * 2008-09-05 2010-03-12 Lfb Biotechnologies STABLE CELLULAR CLONE EXPRESSING A PRION
FR2940446A1 (en) 2008-12-22 2010-06-25 Lfb Biotechnologies METHOD OF DETECTING PRION INFECTION
FR2998373B1 (en) 2012-11-20 2015-01-09 Franklab Sas METHOD FOR MEASURING THE SUITABILITY OF A FORMULATION TO INACTIVATE AN ATNC
FR3005576B1 (en) 2013-05-15 2015-06-19 Lab Francais Du Fractionnement PROCESS FOR INACTIVATING A PRION PROTEIN
BR112020016727A2 (en) * 2018-02-19 2020-12-15 Bayer Healthcare Llc MODIFIED FILTERING MEMBRANE AND METHOD

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605445B1 (en) * 1999-02-22 2003-08-12 Bayer Corporation Rapid method of determining clearance of prion protein

Also Published As

Publication number Publication date
BRPI0413897A (en) 2006-10-24
DK1658494T3 (en) 2012-01-09
FR2859222B1 (en) 2006-01-27
ATE528646T1 (en) 2011-10-15
JP2007503209A (en) 2007-02-22
AU2004269188B2 (en) 2011-04-07
EP1658494A1 (en) 2006-05-24
IL173850A (en) 2012-02-29
FR2859222A1 (en) 2005-03-04
AU2004269188A1 (en) 2005-03-10
EP1658494B1 (en) 2011-10-12
ES2374816T3 (en) 2012-02-22
CA2536688C (en) 2012-11-06
CA2536688A1 (en) 2005-03-10
PL1658494T3 (en) 2012-05-31
WO2005022148A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
EP1930724A4 (en) Various substances supporter, various substances supporter processing apparatus, and method of mentioned processing
IL173850A0 (en) Method for the in vitro titration of an ncta and application thereof in a method for the evaluation and/or monitoring of a biological product production method
GB2392387A (en) Apparatus and method for monitoring biofilm cleaning efficacy
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
ATE294031T1 (en) CLEANING PROCESS WHICH USES ULTRASONIC WAVES
WO2008053482A3 (en) Application of magnetic field to treat tissue
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
WO2006099541A3 (en) Therapeutic wound care product
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
WO2007026251A8 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2009065738A3 (en) Polyoxyalkylenamines for improved fragrance yield
WO2006121684A3 (en) Acyl hydrazones for treating cardiovascular diseases
MX2010001230A (en) System, method and apparatus for processing bone product.
ATE318189T1 (en) CLEANING METHOD USING ULTRASONIC WAVES
WO2010102790A3 (en) Blood treatment machine comprising an apparatus for connecting an external functional device to an arrangement, arrangement including such an apparatus, and connection method
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
MY140061A (en) Improved method for the production of ramipril
AU2003274186A1 (en) Method for monitoring and analyzing a process
TW200504402A (en) Antimicrobial lenses, processes to prepare them and methods of their use
PL371784A1 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
UA83203C2 (en) Thiazol-(bi)cycloalkyl-carboxanilides and their use for fighting against undesirable microorganisms
ZA200601001B (en) Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicament comprising the same
TW200642688A (en) New use of PDE7 inhibitors
WO2007067516A3 (en) Multiple myeloma
WO2006078776A3 (en) Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees